Traffic Lights - Latest Updates

Last updated: 16/08/2016

Other updates on this site
Drug Name Classification Clinical Indication Comments
ACETYLCYSTEINE (UPDATED) Black Usual interstitial pneumonitis (UIP)

Click on drug name for further details

 

ALENDRONIC ACID EFFERVESCENT TABLETS (Binosto®) (NEW) Amber Simple Osteoporosis
BRIVARACETAM (NEW) Red Epilepsy (third line agent)
CALCIPOTRIOL/BETAMETHASONE CUTANEOUS FOAM (Enstilar®) (NEW) Black Psoriasis vulgaris

Not yet reviewed

CANAGLIFLOZIN (NEW) Green Monotherapy in type 2 diabetes

In line with NICE TA 390

DAPAGLIFLOZIN (NEW) Green Monotherapy in type 2 diabetes

In line with NICE TA 390

EMPAGLIFLOZIN (NEW) Green Monotherapy in type 2 diabetes

In line with NICE TA 390

LEVOFLOXACIN NEBULISER SOLUTION (Quinsair®) (NEW) Black Cystic fibrosis

Not yet reviewed

LIOTHYRONINE (NEW) (UPDATED) Red Concomitant therapy with thyroxine

For patients who have hypothyroidism who have had inadequate response to thyroxine alone, in line with guidance

MacuLEH Light® (NEW) Black Age-related macular degeneration

Not approved by local committee see Guideline

SACUBITRIL / VALSARTAN (Entresto®) (UPDATED) Red Heart failure
SELEXIPAG (Uptravi®) (NEW) Black Pulmonary arterial hypertension

Not yet reviewed

Other Updates on this Website

Recent documents from LMSG and TAS

About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more